Ibrance®, palbociclib, is a kinase inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with
• an aromatase inhibitor as initial endocrine based therapy in postmenopausal women e.g. Letrozole
or
• fulvestrant in women with disease progression following endocrine therapy
To Read More>>
To check if our service suits your case
We need to talk
Improve therapeutic outcomes, prolong life and quality of life, are our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.
Article categories
Popular topics
